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 Antibody molecules are composed by the fragment crystallizable (Fc) and antigen-binding fragment (Fab) that contains the light chain 
and a portion of the heavy chain. The Fab fragment is further divided into the variable fragment (Fv), the smallest fragment that 
retains antigen-binding activity via contacts with both the heavy and light chains. The two chains of the Fab fragment are held 
together by a disulfide bond whereas the two chains of the Fv are coupled either by a flexible polypeptide linker or by a disulfide bond 
(scFv).  
 
Antibody moieties can be generated through: 
• Chemical processing  reducing agents or enzymatic digestion (pepsin and papain). 
• Genetic formation  phage display. 
 
Requirements of the antibody component to take into consideration: 
• Specificity and binding affinity. 
• Lack of immunogenicity. 
• Conservation in systemic circulation. 
• Internalization ability.  
• Production cost.  
 
For this requirements, and specially for the RES rapid clearance due to the immunogenicity of the fragment crystallizable (Fc) chain, 
nowadays Fab′, F(ab′)2, Fv and scFv antibody fragments are becoming more popular rather than whole antibodies.  
 
For the antibody attachment to the liposomes, the method most extensively used is the maleimide-PEG. It is based on the conjugation 
by means of thio-ether bonds between thiolated antibodies and liposomes containing Mal-PEG-polyethylene-glycol-
distearoylphosphatidylethanolamine (Mal-PEG-DSPE). This method results in stable covalent bonds and has high coupling efficiency, 
especially if applied to Fab′ or scFv fragments containing reduced sulfhydryl groups.  
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• Scientific literature search on PubMed, Web of Science database and Wiley Online Library: recent general reviews and 
papers of immunoliposomes for cancer treatment were selected according to their quality and data of publication. 
• Pharmaceutical literature research on Clinical trials database, Food and Drug Administration and European medicines 
agency: only marketed or under clinical phases pharmaceutical formulations were analyzed.  
 
Liposomes are phospholipid bilayered spheres that have become increasingly interesting as chemotherapeutic agents nanocarriers. 
Mainly, antitumor drugs encapsulation minimizes their toxicity and increases accumulation at the target site(s), thus leading to a 
higher therapeutic index.   
 
The aims of the present review are: 
• To introduce the liposomes formation and pharmacokinetics. 
• To enumerate some antibody derivatization and conjugation strategies.  
• To analyze advances in chemotherapeutic immunoliposomes under in clinical level. 
• To mention some immunoliposomes applications. 
 
Liposomal nanoparticles can passively target tumors owing to the enhanced permeability and retention (EPR) effect. However, 
nowadays liposomes can be optimized enhancing the ability to specifically recognize and bind target tissues by means of  the high 
affinity interaction of some molecules.  
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Liposomes are the result of the hydration of dry lipids films. These enclosed spherical vesicles are flexible, biocompatible and 
biodegradable, easy to prepare and have small particle size yet within high loading capacity. 
In general, liposomal production includes these 5 stages:  
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Abbreviations: DXR (doxorubicin), DNAp (DNA plasmid), GAH (goat anti-human), EGFR (epidermal growth factor receptor) , HER2 (human EGFR 2), TfR 
(transferrin receptor), C225 (anti-EGFR antibody), F5cys (anti-HER2 scFv ), maleimidated dipalmitoyl-phosphatidylethanolamine (Mal-DPPC), Mal-PEG-
polyethylene-glycol-distearoylphosphatidylethanolamine (Mal-PEG-DSPE), MP-PEG-DSPE (maleimidopropylamide-PEG-DSPE), DOTAP (1,2-Dioleoyl-3-
trimethylammonium propane), MPB-DOPE (N-maleimido-phenylbutyrate-dioleoylphosphatidylethanolamine), HoKC (histidylated oligolysine peptide). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunoliposomes under clinical trials 
 
Immunoliposomes are currently being used for drug delivery, diagnosis, imaging, cosmetics, gene therapy and immunotherapy. 
Other applications 
 
Despite the little clinical development to date, results suggest that antibody-coupled liposomes appear to be a promising 
strategy for targeted chemotherapy: 
 
• Immunoliposomal formulations have shown  to reduce side effects. 
• Targeted liposomes enhance local tumor cytotoxicity via clathrin-dependent endocytosis and the bystander effect and 
overcome multidrug resistance. 
• scFv coupling is the preferred conjugation strategy since it offers slower clearance, lower production cost and the ability to 
engineer scFv with the desired affinity and specificity using phage display. 
 
Future directions to take into consideration:  
 
• Pharmacokinetics of drug unloading should be studied thoroughly for a better understanding of immunoliposomes 
preparation methods to achieve long circulation time, efficient tumor targeting and optimal release profiles of 
chemotherapeutic agents.  
• Standards for parameters analysis of in vitro and in vivo models are required as well as well-defined criteria and 
comprehensive guidelines for both regulatory approval and large-scale industrial production.   
• Major research effort should be undertaken to improve immunoliposomal properties and to find the most relevant targets 
on tumor cells, thus creating a potential new avenue for safe and effective targeted delivery of anticancer drugs in patients. 
 
Conclusions and future directions  
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Advantages 
• Enhanced therapeutic index 
• Site-avoidance mechanism 
• Drug loading versatility 
• Specific targeting 
• Increased half-life 
circulation 
• Intracellular drug delivery 
Disadvantages 
• Sometimes immunogenic 
• High cost 
• Difficult barrier penetration 
 
Table 2. Antibody-targeted liposomes for cancer treatment in clinical trial phase. 
Product Drug Target Ab fragment Formulation Condition Status  
MCC-465 DXR GAH F(ab’)2 GAH F(ab’)2-Mal-DPPC Gastric and colorectal cancer Phase I 
anti-EGFR-ILs-dox DXR EGFR Fab’ C225 Fab’- Mal-PEG-DSPE Solid tumor Phase I 
MM-302 DXR HER2 scFv F5cys-MP-PEG-DSPE Breast cancer Phase II/III  
SGT-53 P53 DNAp TfR scFv TfRscFv- DOTAP:MPB-DOPE-HoKC Solid tumors, pancreatic cancer and glioblastoma Phase I/II 
SGT-94 RB94 DNAp TfR scFV TfRscFv-DOTAP:MPB-DOPE-HoKC Solid tumors Phase I 
  
Table 1. Liposome generations characteristics 
First generation 
Liposomes 
Second generation 
PEGylated 
liposomes 
Third generation 
PEGylated 
immunoliposomes 
Half-life circulation Short (RES) Long Medium 
Solubility Low High High 
Pharmacokinetics Dose-dependent Dose-independent Dose-independent 
Leakage High Low Low 
Targeting Passive Passive Active 
Delivery Uncontrolled Uncontrolled Intracellular 
Drying down lipids from organic 
solvent: 
• Phosphatidylethanolamine 
• Cholesterol 
• Others 
Lipid 
dispersion 
in aqueous 
media 
 
Drug loading 
•  During formation 
•  After formation 
•    Passively 
•    Actively 
Liposome 
purification 
 
Product 
viability 
analysis 
C B 
Figure 2. A) 64Cu-MM-302 enhanced targeting to HER2-overexpressing 
breast carcinoma (BT474-M3). Adapted from Lee H et al., 2015. B) In vivo 
antitumor activities of DXR (doxorubicin), PLD (PEGylated liposome DRX), 
and MCC-465 in mice bearing a colorectal adenocarcinoma xerograph. 
Adapted from Hamaguchi T et al., 2004. C) p53 transgene tumor 
expression. Adapted from Senzer N et al., 2013.  
Passive targeting   EPR effect  
• Extensive angiogenesis 
• Defective vascular architecture 
• Impaired lymphatic drainage 
• Increased production of permeability mediators 
Active targeting  Specific binding 
• Whole antibodies or some fragments 
• High affinity molecules (i.e. folate or transferrin) 
 
 
Antibodies coupling to the liposomal surface for active 
targeting generates what is known as immunoliposome.  
 
Several types of liposomes are currently approved by the 
US Food and Drug Administration (FDA) although 
immnoliposomes still are under clinical trial phases.  
 
Here there are some of the advantages and disadvantages 
of immunoliposomes as nanocarriers: 
  
 
First generation liposomes suffered of a 
short half-life due to rapid elimination 
from the circulation by the cells of the 
reticuloendothelial system (RES) as they 
are recognized as foreign particles. For this 
reason, the surface of the liposome 
membrane was remodelled using 
hydrophilic polymers, usually polyethylene 
glycol (PEG), providing an additional 
surface hydration layer. The surface 
hydration, also known as PEGylation, 
enlarges liposomal circulation half-life and 
confers dose-independent 
pharmacokinetics. Finally  PEGylated 
liposomes were attached to antibodies to 
gain specific targeting and clathrin-
dependent endocytosis .  
 
MCC-465 
 
• Dose limiting toxicity is myelosuppression and appetite loss 
whereas neither palmar–plantar erythrodysesthesia nor 
cardiotoxicity are observed.  
• Most patients treated stabilize the disease, although no 
objective antitumor response is seen.  
 
C225-ILS-DOX 
 
• EGFR expression in tumors is up to three orders of 
magnitude higher than EGFR expression in normal tissue.  
• Tumor citotoxicity is higher as a result of the intracellular 
unloading and the bystander effect.  
 
MM-302 
 
• Advanced/metastatic breast cancer patients show enhanced 
treatment efficacy.  
• 64Cu marked MM-302 was tested for PET/CT imaging. 
 
SGT-53 and SGT-94 
 
• MPB-DOPE and HoKC facilitate DNA unloading in endosome 
acidic conditions.  
• SGT-53 and SGT-94 are loaded with  p53 and Rb94 
(retinoblastoma) DNA plasmids respectively  that aim to 
restore the loss of these tumor suppressor functions present 
in most human cancers.  
• Both formulations are well tolerated, exhibit anticancer 
activity, and also supply evidence of targeted transgene 
expression in metastatic tumors. 
 
 
Figure 1. Schematic representation 
of different antibody fragments.   
  
